Corvus Pharmaceuticals IncChange company Symbol lookupSelect an option...CRVS Corvus Pharmaceuticals IncALTR Altair Engineering IncCVX Chevron CorpASCB ASPAC II Acquisition CorpSTRS Stratus Properties IncESMC Escalon Medical CorpATO Atmos Energy CorpLVS Las Vegas Sands CorpHUBB Hubbell IncPM Philip Morris International IncGo
Corvus Pharmaceuticals, Inc. is an immunology biopharmaceutical company focused on developing drugs and antibodies that target the critical cellular elements of the immune system. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
|
|
|
|
| |
Company Profile
Corvus Pharmaceuticals, Inc. is an immunology biopharmaceutical company focused on developing drugs and antibodies that target the critical cellular elements of the immune system. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 0.42x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Richard A. MillerChmn.
- Leiv LeaCFO
- William Benton JonesSr.VP
- Ian Clark
- Elisha P. Gould
Address
- 863 Mitten Rd Ste 102
- Burlingame, CA 94010-1311
- Phone: (650) 900-4520
- Fax: (302) 655-5049
- http://www.corvuspharma.com/
Insider Trading
During the most recent quarter, 51K shares were bought in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.